Published in Nature Genetics · View the paper (DOI)
A Vanderbilt-led study identifies a compound that can reverse the malignant reprogramming of metastatic pancreatic cancer cells. The research found that distant metastases undergo massive epigenetic changes that enable tumor formation, but these changes can be reversed with the inhibition of phosphogluconate dehydrogenase enzyme.
Coverage from 2 institutions